Viglioglia P, Jones M L, Peets E A
Hospital J. A. Fernandez, Buenos Aires, Argentina.
J Int Med Res. 1990 Nov-Dec;18(6):460-7. doi: 10.1177/030006059001800603.
A randomized, investigator-blind, parallel-group trial was conducted to compare the safety and efficacy of 0.1% mometasone furoate cream applied once daily with that of 0.1% betamethasone valerate cream applied twice daily in patients (n = 69) with allergic contact dermatitis, atopic dermatitis and other steroid-responsive dermatoses. After 3 day's treatment improvement in conditions averaged 38.2% and 39.3%, respectively, in the mometasone and betamethasone treatment groups, and after 21 days average improvements were 93.6% and 96.5%, respectively. The physicians' global evaluation of overall change in disease status and the patients' evaluation of treatment also indicated that the two treatment regimens produced comparable, rapid and progressive improvements in the patients' conditions, and no local side-effects were reported. It is concluded that mometasone furoate was as effective as betamethasone valerate in the treatment of a variety of steroid-responsive dermatoses, although mometasone furoate was applied only half as frequently.
进行了一项随机、研究者盲法、平行组试验，以比较0.1%糠酸莫米松乳膏每日一次与0.1%戊酸倍他米松乳膏每日两次在69例过敏性接触性皮炎、特应性皮炎和其他对类固醇有反应的皮肤病患者中的安全性和疗效。治疗3天后，糠酸莫米松治疗组和戊酸倍他米松治疗组的病情改善平均分别为38.2%和39.3%，21天后平均改善分别为93.6%和96.5%。医生对疾病状态总体变化的整体评估以及患者对治疗的评估也表明，两种治疗方案在患者病情上产生了相当、快速和渐进的改善，且未报告局部副作用。得出的结论是，糠酸莫米松在治疗各种对类固醇有反应的皮肤病方面与戊酸倍他米松一样有效，尽管糠酸莫米松的使用频率仅为后者的一半。
